Investing.com - Erytech Pharma ADR reported on Monday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Erytech Pharma ADR announced earnings per share of €-0.6871 on revenue of €1.46M. Analysts polled by Investing.com anticipated EPS of €-0.6526 on revenue of €1.47M.
Erytech Pharma ADR shares are down 3% from the beginning of the year and are trading at €2.500 , down-from-52-week-high.They are under-performing the STOXX 600 which is up 22.86% from the start of the year.
Erytech Pharma ADR follows other major Healthcare sector earnings this month
Erytech Pharma ADR's report follows an earnings beat by J&J on October 19, who reported EPS of €2.6 on revenue of €23.34B, compared to forecasts EPS of €2.35 on revenue of €23.64B.
Pfizer had beat expectations on November 2 with third quarter EPS of €1.34 on revenue of €24.09B, compared to forecast for EPS of €1.08 on revenue of €22.58B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar